Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q2 2021 · 10-Q
Revenue$0.00$0.00— vs Q2 2020 Net Income-$4.86M-$4.86MN/M vs Q2 2020 EPS Diluted-$0.15-$0.15N/M vs Q2 2020 Operating Income-$4,381,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
derived
ended Jun 30, 2021 · filed Aug 23, 2021 · 54 d after period end